MaxCyte, Inc. Total Voting Rights (3476F)
July 07 2023 - 4:23AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 3476F
MaxCyte, Inc.
07 July 2023
MaxCyte, Inc.
("MaxCyte" or the "Company")
Total Voting Rights
Gaithersburg, Maryland - 7 July 2023: MaxCyte Inc., (NASDAQ:
MXCT; LSE: MXCT), a leading commercial cell - engineering company
focused on providing enabling platform technologies to advance
innovative cell-based research as well as next-generation cell
therapeutic discovery, development and commercialization, announces
that pursuant to its block admission facility, since 31 May 2023 it
has issued 67,537 of common stock, $0.01 par, of the Company
("Common Stock") in satisfaction of the exercise of share
options.
Total voting rights
As at 30 June 2023, the total issued stock capital of the
Company following the recent issue of the new Common Stock is
103,134,585 shares of Common Stock. Shareholders in the Company may
use this figure as the denominator for the calculations by which
they will determine if they are required to notify their interest
in, or a change to their interest in, the stock capital of the
Company.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group +1 415-937-5400
David Deuchler, CFA ir@maxcyte.com
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize
the potential of cells to improve patients' lives. We have spent
more than 20 years honing our expertise by building best-in-class
platforms, perfecting the art of the transfection workflow, and
venturing beyond today's processes to innovate tomorrow's
solutions. Our ExPERT(TM) platform, which is based on our Flow
Electroporation (R) technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM), GTx(TM)
and VLx (TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology, as well as technical and
regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com and follow us on
Twitter and LinkedIn .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRNKOBBFBKKNOK
(END) Dow Jones Newswires
July 07, 2023 04:23 ET (08:23 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024